Lonca is a CD19‐targeting antibody‐drug conjugate that demonstrated durable efficacy and an acceptable safety profile in heavily pretreated patients with R/R DLBCL in the LOTIS‐2 study [15]. Here, CD19 is linked to diffuse large B-cell lymphoma.